Kusic Natasa, Tomic Spiric Vesna, Arandjelovic Snezana, Peric Popadic Aleksandra, Bozic Antic Ivana, Dimitrijevic Milan, Miskovic Rada, Stefanovic Ljiljana, Plavsic Aleksandra
Clinic of Allergy and Immunology, University Clinical Centre of Serbia, 11000 Beograd, Serbia.
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Healthcare (Basel). 2024 Mar 7;12(6):601. doi: 10.3390/healthcare12060601.
Drug desensitization allows for safe administration of a drug to a patient with a previous hypersensitivity reaction. Successful desensitization protocols have been described for different medications, including protocols for oncology patients. Few cases of desensitization to sorafenib and imatinib have been described in the literature so far.
The objective of this paper is to describe the process of the sorafenib and imatinib drug hypersensitivity diagnosis and desensitization process in two patients.
Two oncology patients who experienced non-immediate hypersensitivity reactions to sorafenib and imatinib underwent desensitization to these drugs. We designed a protocol for the first patient and used a modified protocol from the literature for the second patient.
By using a slow desensitization technique and gradual tapering of corticosteroids and antihistamines, both patients reached the target dose of the incriminated drug.
Desensitization to sorafenib and imatinib can be an effective therapeutic option in patients with hypersensitivity to those medications, without alternative treatment options.
药物脱敏可使曾有过超敏反应的患者安全使用某种药物。已针对不同药物描述了成功的脱敏方案，包括针对肿瘤患者的方案。迄今为止，文献中很少有关于索拉非尼和伊马替尼脱敏的病例报道。
本文旨在描述两名患者对索拉非尼和伊马替尼药物超敏反应的诊断过程及脱敏过程。
两名对索拉非尼和伊马替尼发生非速发型超敏反应的肿瘤患者接受了这两种药物的脱敏治疗。我们为第一名患者设计了一个方案，并对第二名患者使用了文献中的改良方案。
通过采用缓慢脱敏技术以及逐渐减少皮质类固醇和抗组胺药的用量，两名患者均达到了可疑药物的目标剂量。
对于对索拉非尼和伊马替尼过敏且没有其他替代治疗选择的患者，对这些药物进行脱敏可能是一种有效的治疗选择。
